Litcius/Paper detail

Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System

Toru Ogura, Chihiro Shiraishi

2023Clinical Drug Investigation15 citationsDOI

Topics & Concepts

AlogliptinSaxagliptinSitagliptinAdverse Event Reporting SystemMedicineVildagliptinAdverse effectLinagliptinDipeptidyl peptidase-4Internal medicineDipeptidyl peptidase-4 inhibitorDiabetes mellitusType 2 diabetesPharmacologyEndocrinologyDiabetes Treatment and ManagementPharmacovigilance and Adverse Drug ReactionsAtrial Fibrillation Management and Outcomes
Comparison of Adverse Events Occurred During Administration of Dipeptidyl Peptidase-4 Inhibitor in Patients with Diabetes Using FDA Adverse Event Reporting System | Litcius